COVID-19 Statement
Careers
Contact Us

Our Focus

We are developing potential medicines to improve the healthspan of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Pipeline

We’re advancing muscle biology-driven treatments for diseases characterized by compromised muscle function, muscle weakness, and fatigue.
Clinical Trials

We have conducted more than 50 clinical trials as we strive to bring important new medicines to patients with diseases like ALS, heart failure, HCM and SMA.
- Helpful Resources
- Access Policy

Company

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing muscle activators and inhibitors.
Culture

Our diverse, inclusive and respectful culture is foundational to our success and essential to building a strong team.
Investors & Media

Cytokinetics’ unparalleled expertise has kept it at the forefront of drug discovery and development for diseases impacting muscle performance.

Image Description

meet ourleaders

John Chabala, Ph.D.

Former President and CSO, Pharmacopeia; Former VP, Discovery Chemistry, BMS; Former Executive Director, Basic Chemistry, Merck

Scientific Advisory Board

Charles Brenner, Ph.D.
Roger A. Fielding, Ph.D.

Our Focus
Pipeline
Clinical Trials
- Helpful Resources
- Access Policy
Company
Culture
Investors & Media

© 2020 Cytokinetics, Inc. All rights reserved.

Updated Privacy Policy
Cookie Policy
TERMS OF USE